AKR1C3 as a target in castrate resistant prostate cancer

被引：119

作者：

Adeniji, Adegoke O. ^{[1
]}

Chen, Mo ^{[1
]}

Penning, Trevor M. ^{[1
,2
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Ctr Excellence Environm Toxicol, Philadelphia, PA 19104 USA

来源：

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 2013年 / 137卷

关键词：

Type 5 17 beta-hydroxysteroid dehydrogenase; Prostaglandin F synthase; Prostate cancer; Androgens; Nonsteroidal anti-inflammatory drugs; KETO REDUCTASE SUPERFAMILY; CINNAMIC ACID-DERIVATIVES; PROSTAGLANDIN-F SYNTHASE; ANDROGEN RECEPTOR; SELECTIVE INHIBITORS; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; ABIRATERONE ACETATE; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE AKR1C3; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL;

D O I：

10.1016/j.jsbmb.2013.05.012

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Aberrant androgen receptor (AR) activation is the major driver of castrate resistant prostate cancer (CRPC). CRPC is ultimately fatal and more therapeutic agents are needed to treat this disease. Compounds that target the androgen axis by inhibiting androgen biosynthesis and or AR signaling are potential candidates for use in CRPC treatment and are currently being pursued aggressively. Aldo-keto reductase 10 (AKR1C3) plays a pivotal role in androgen biosynthesis within the prostate. It catalyzes the 17-ketoreduction of weak androgen precursors to give testosterone and 5 alpha-dihydrotestosterone. AKR1C3 expression and activity has been implicated in the development of CRPC, making it a rational target. Selective inhibition of AKR1C3 will be important, however, due to the presence of closely related isoforms. AKR1C1 and AKR1C2 that are also involved in androgen inactivation. We examine the evidence that supports the vital role of AKR1C3 in CRPC and recent developments in the discovery of potent and selective AKR1C3 inhibitors. This article is part of a Special Issue entitled 'CSR 2013'. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：136 / 149

页数：14

共 80 条

[11] Cinnamic acids as new inhibitors of 17β-hydroxy steroid dehydrogenase type 5 (AKR1C3) [J].

Brozic, P ;

Golob, B ;

Gomboc, N ;

Rizner, TL ;

Gobec, S .

MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2006, 248 (1-2) :233-235

[12] Selective Inhibitors of Aldo-Keto Reductases AKR1C1 and AKR1C3 Discovered by Virtual Screening of a Fragment Library [J].

Brozic, Petra ;

Turk, Samo ;

Adeniji, Adegoke O. ;

Konc, Janez ;

Janezic, Dusanka ;

Penning, Trevor M. ;

Rizner, Tea Lanisnik ;

Gobec, Stanislav .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (17) :7417-7424

[13] Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms:: Oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione [J].

Burczynski, ME ;

Harvey, RG ;

Penning, TM .

BIOCHEMISTRY, 1998, 37 (19) :6781-6790

[14] Steroidal lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 5: Chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities [J].

Bydal, Patrick ;

Luu-The, Van ;

Labrie, Fernand ;

Poirier, Donald .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (02) :632-644

[15] An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies [J].

Byrns, Michael C. ;

Steckelbroeck, Stephan ;

Penning, Trevor M. .

BIOCHEMICAL PHARMACOLOGY, 2008, 75 (02) :484-493

[16] Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights [J].

Byrns, Michael C. ;

Jin, Yi ;

Penning, Trevor M. .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2011, 125 (1-2) :95-104

[17] Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): Role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs [J].

Byrns, Michael C. ;

Penning, Trevor M. .

CHEMICO-BIOLOGICAL INTERACTIONS, 2009, 178 (1-3) :221-227

[18] Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors [J].

Cai, Changmeng ;

Chen, Sen ;

Ng, Patrick ;

Bubley, Glenn J. ;

Nelson, Peter S. ;

Mostaghel, Elahe A. ;

Marck, Brett ;

Matsumoto, Alvin M. ;

Simon, Nicholas I. ;

Wang, Hongyun ;

Chen, Shaoyong ;

Balk, Steven P. .

CANCER RESEARCH, 2011, 71 (20) :6503-6513

[19] Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer [J].

Chang, Kai-Hsiung ;

Li, Rui ;

Papari-Zareei, Mahboubeh ;

Watumull, Lori ;

Zhao, Yan Daniel ;

Auchus, Richard J. ;

Sharifi, Nima .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (33) :13728-13733

[20] Prostaglandin F2α stimulates the Raf/MEK1/mitogen-activated protein kinase signaling cascade in bovine luteal cells [J].

Chen, DB ;

Westfall, SD ;

Fong, HW ;

Roberson, MS ;

Davis, JS .

ENDOCRINOLOGY, 1998, 139 (09) :3876-3885

← 1 2 3 4 5 6 7 8 →